Advances in Liquid Biopsies


Monday, Jan. 13

Tuesday, Jan. 14

Wednesday, Jan. 15

Thursday, Jan. 16

Monday, Jan. 13

Welcome and Keynote Address
5:30-6:30 p.m.

Plasma DNA-based molecular diagnostics: Fragments, circles, and beyond
Dennis Lo, The Chinese University of Hong Kong, Shatin New Territories, China

Opening Reception
6:30-8 p.m.

Top of page

Tuesday, Jan. 14

Continental Breakfast
7-8 a.m.

Plenary Session 1: Early Detection with ctDNA
Session Chair: Luis A. Diaz, Jr., Memorial Sloan Kettering Cancer Center, New York, New York
8-10:10 a.m.

Multicancer detection of early-stage cancers with simultaneous tissue localization using a plasma cfDNA-based targeted methylation assay
Eric T. Fung, GRAIL, Inc., Menlo Park, California

Early detection and characterization of cancer using noninvasive liquid biopsies
Victor E. Velculescu, Johns Hopkins Sidney Kimmel Comprehensive Cancer Center, Baltimore, Maryland

Sensitive tumor detection and classification using methylome analysis of plasma cfDNA
Daniel D. De Carvalho, Princess Margaret Cancer Centre, Princess Margaret Cancer Centre, University Health Network; University of Toronto, Toronto, Ontario, Canada

Detection of somatic mutations and HPV in saliva of patients with head and neck squamous cell carcinoma
Nishant Agrawal, University of Chicago Pritzker School of Medicine, Chicago, Illinois

ctDNA shedding dynamics dictate early lung cancer detection potential*
Johannes Reiter, Stanford University, Stanford, California

Epigenetic biomarkers in cell-free DNA for early detection of high grade serous ovarian carcinoma*
Ben Yi Tew, University of Southern California, Los Angeles, California

10:10-10:30 a.m.

Plenary Session 2: MRD and Early Stage Disease
Session Chair: Nicholas C. Turner, Royal Marsden Hospital Institute of Cancer Research, London, England
10:30 a.m.-12:30 p.m.

ctDNA and MRD in colorectal cancer: Time to re-invent adjuvant clinical trials
Jeanne Tie, Peter MacCallum Cancer Center, Melbourne, Australia

Molecular relapse and residual disease in breast cancer
Nicholas C. Turner

Liquid biopsies for personalized monitoring and detection of cancer
Maximilian Diehn, Stanford University, Stanford, California 

Use of liquid biopsy to facilitate drug development in early stage disease - FDA perspective
Julia A. Beaver, Food and Drug Administration, Silver Spring, Maryland 

Special Presentation
12:30-12:45 p.m.

The promise of liquid biopsy in the early detection of cancer: Hope or hype?  
Sudhir Srivastava, National Cancer Institute, Bethesda, Maryland

Lunch (on Own)
12:30-2:30 p.m.

Plenary Session 3: Hematologic Malignancies
Session Chair: Irene M. Ghobrial, Dana-Farber Cancer Institute, Boston, Massachusetts
2:30-4:15 p.m.

Liquid biopsies as biomarkers of disease progression in multiple myeloma
Irene M. Ghobrial

Clinical applications of liquid biopsy in multiple myeloma
Suzanne Trudel, University of Toronto University Health Network, Toronto, Ontario, Canada

Genome-wide 5-hydroxymethylcytosine profiles in circulating cell-free DNA and survival in patients with multiple myeloma*
Brian Chiu, University of Chicago, Chicago, Illinois

Clonal landscapes of hematologic malignancies redefined by ultra-sensitive duplex sequencing*
Jake Higgins, TwinStrand Biosciences, Seattle, Washington

Radiation-assisted Amplification Sequencing (RAMP-Seq): Evaluating the use of stereotactic body radiation therapy (SBRT) for enriching circulating tumor DNA in liquid biopsies*
Christopher Boniface, Oregon Health & Science University, Portland, Oregon

Poster Session A / Reception
4:15-6:45 p.m.

Wednesday, Jan. 15

Continental Breakfast
7-8 a.m.

Plenary Session 4: Genotyping, Monitoring of Advanced Disease, and Molecular Resistance (Part I)
Session Chair: Maximilian Diehn, Stanford University, Stanford, California
8-10 a.m.

Response in plasma cfDNA as an early marker of treatment effect in advanced cancer
Geoffrey R. Oxnard, Dana-Farber Cancer Institute, Boston, Massachusetts

Tracking and targeting colorectal cancer evolution
Alberto Bardelli, University of Turin School of Medicine, Candiolo To, Italy

Liquid biopsies for tracking molecular resistance in cancer
Sarah-Jane Dawson, Peter MacCallum Cancer Center, Melbourne, Australia

Clonal evolution over narrow time frames via circulating tumor DNA in metastatic breast cancer*
Daniel Stover, Ohio State University Comprehensive Cancer Center, Columbus, Ohio

MSI detection in plasma cfDNA: MSI as a marker of disease burden*
Preethi Srinivasan, Memorial Sloan Kettering Cancer Center, New York, New York

10-10:30 a.m.

Plenary Session 5: Genotyping, Monitoring of Advanced Disease, and Molecular Resistance (Part II)
Session Chair: Nitzan Rosenfeld, Cancer Research UK Cambridge Research Institute, Cambridge, England
10:30 a.m.-12:30 p.m.

Liquid biopsies: Implications for therapeutic response/resistance and prognosis
Razelle Kurzrock, University of California San Diego Moores Cancer Center, La Jolla, California 

Enhancing detection of ctDNA in patients with early stage or residual disease
Nitzan Rosenfeld

Comprehensive genomic profiling of cell-free DNA enables treatment response monitoring
Viktor Adalsteinsson, Broad Institute, Cambridge, Massachusetts 

Validation and clinical implementation of MSK-ACCESS, an ultra-deep sequencing assay for non-invasive somatic mutation profiling*
A. Rose Brannon, Memorial Sloan Kettering Cancer Center, New York, New York

Frequency and etiology of ctDNA-positive metastatic prostate cancer with BRCA2, ATM, or CDK12 mutations*
Evan Warner, Vancouver Prostate Centre, Vancouver, British Columbia, Canada

Poster Session B / Lunch
12:30-3 p.m.

Plenary Session 6: Circulating Tumor Cells
Session Chair: Caroline Dive, Cancer Research UK Manchester Institute, Manchester, England
3-5 p.m.

Molecular signatures of circulating tumor cells
Daniel A. Haber, Massachusetts General Hospital, Charlestown, Massachusetts 

Multiple uses of circulating tumor cells in lung cancer?
Caroline Dive

Circulating tumor cells: Biology and clinical applications as liquid biopsy
Klaus Pantel, University Medical Center Hamburg-Eppendorf, Hamburg, Germany

Analytical validation and preliminary clinical utility of PD-L1 and HLA I expression profiling of circulating tumor cells using automated exclusion-based sample preparation technology*
Jennifer Schehr, University of Wisconsin, Madison, Wisconsin

Multimodal analysis of circulating tumor cell RNA, circulating cell-free DNA, and genomic DNA from a single blood sample collected Into a PAXgene Blood ccfDNA Tube*
Anna Babayan, PreAnalytiX, Hombrechtikon, Switzerland

Thursday, Jan. 16

Continental Breakfast
7-8 a.m.

Plenary Session 7: Emerging Approaches
Session Chair: Muneesh Tewari, University of Michigan, Ann Arbor, Michigan
8-10 a.m.

Exploiting the biology of exosomes for diagnosis and treatment of cancer
Raghu Kalluri, University of Texas MD Anderson Cancer Center, Houston, Texas

Tumor-educated platelets for the detection of cancer
Thomas Würdinger, Vrije University Medical Center, Amsterdam, Netherlands

Phospho-RNA-seq: A liquid biopsy approach for cell-free mRNA/lncRNA profiling
Muneesh Tewari

Detection of EV-based signatures in prostate cancer using microflow cytometry and machine learning*
John Lewis, University of Alberta, Edmonton, Alberta, Canada

Comprehensive detection of ctDNA in localized head and neck cancer by genome- and methylome-based analysis*
Justin Burgener, Princess Margaret Cancer Centre, Toronto, Ontario, Canada

10-10:30 a.m.

Plenary Session 8: Alternative "Fluids"
Session Chair: George J. Netto, University of Alabama at Birmingham, Birmingham, Alabama
10:30 a.m.-12 p.m.

A deep dive into the cfDNA pool: Clonal hematopoiesis as a major source of somatic mutations
Pedram Razavi, Memorial Sloan Kettering Cancer Center, New York, New York

Liquid biopsy in precision pathology: Plasma and beyond!
George J. Netto, University of Alabama at Birmingham, Birmingham, Alabama

Sub-nucleosomal fragmentation in urine cell-free DNA*
Havell Markus, Translational Genomics Research Institute, Phoenix, Arizona

Charting extracellular transcriptomes in The Human Biofluid RNA Atlas*
Eva Hulstaert, Ghent University, Ghent, Belgium

Closing Remarks
12-12:15 p.m.